계명대학교 의학도서관 Repository

Aspirin induces apoptosis in YD-8 human oral squamous carcinoma cells through activation of caspases, down-regulation of Mcl-1, and inactivation of ERK-1/2 and AKT

Metadata Downloads
Author(s)
남기영김종배황상희박종욱장병철최미선류남희
Alternative Author(s)
Nam, Ki YoungKim, Jong BaeHwang, Sang HeePark, Jong WookJang, Byeong ChurlChoe, Mi SunRyoo, Nam Hee
Publication Year
2010
Keyword
AspirinApoptosisYD-8 OSC cellsCaspasesMcl-1ERK-1/2AKTNF-κB
Abstract
NSAIDs and COX-2 inhibitors show anti-cancer activities in many cancer cells. In this study, we investi-
gated the effects of NSAIDs (aspirin or indomethacin) and COX-2 inhibitor (NS-398) on growth of YD-8
human oral squamous carcinoma cells. Interestingly, among drugs tested, aspirin showed strongest
inhibitory effects on viability and survival of YD-8 cells. Profoundly, aspirin treatment resulted in severe
cell shrinkage and nuclear DNA fragmentation in YD-8 cells, suggesting the aspirin-induced apoptosis in
YD-8 cells. Data of Western blot further demonstrated that aspirin treatment caused activation of casp-
ases, down-regulation of Mcl-1 protein, dephosphorylation of ERK-1/2 and AKT, and also IjB-a proteol-
ysis-dependent NF-jB activation in YD-8 cells. Aspirin, however, had no effect on expressions of Bcl-2,
XIAP, and HIAP-1 in YD-8 cells. Importantly, pretreatment with z-VAD-fmk, a pan-caspase inhibitor
blocked the aspirin-induced apoptosis and Mcl-1 down-regulation in YD-8 cells. These findings collec-
tively suggest that aspirin induces apoptosis in YD-8 cells and the induction may be correlated to activa-
tion of caspases, caspase-dependent Mcl-1 proteolysis, inactivation of ERK-1/2 and AKT, and activation of
NF-jB. It is suggested that aspirin may be applied a potential anti-cancer drug against human oral squa-
mous carcinoma.
2010 Elsevier Ltd. All rights reserved. Keywords:
Aspirin
Apoptosis
YD-8 OSC cells
Caspases
Mcl-1
ERK-1/2
AKT
NF-jB
Authorize & License
  • AuthorizeOpen
  • EmbargoForever
Files in This Item:

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.